Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
The Clorox Company's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $10.0B | |
|---|---|---|
| P/E (forward) | 14.2x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2026-06-30 | Trend |
| Revenue | $7.11B | $7.39B | $7.09B | $7.10B | $6.72B | -1.4% |
| Gross profit | $2.55B | $2.91B | $3.05B | $3.21B | $2.84B | +2.8% |
| Operating income | $713.0M | $328.0M | $488.0M | $1.17B | $921.0M | +6.6% |
| Net income | $462.0M | $149.0M | $280.0M | $810.0M | $587.0M | +6.2% |
| EPS (diluted) | $3.73 | $1.20 | $2.25 | $6.52 | $5.54 | +10.4% |
| EBITDA | $937.0M | $564.0M | $723.0M | $1.39B | $921.0M | -0.4% |
| R&D | $132.0M | $138.0M | $126.0M | $121.0M | $116.0M | -3.2% |
| SG&A | $954.0M | $1.18B | $1.17B | $1.12B | $317.0M | -24.1% |
Recent company headlines from major financial publishers.
Modal turnaround path where retail distribution breadth recovers while promotional reinvestment supports Fair value of $104.80.
Turnaround execution outpaces expectations as consumer loyalty drives retail shelf replenishment and margin expansion toward Potential value of $185.52.
| Ke ↓ / g → | 0.5% | 0.5% | 1.0% | 1.5% | 2.0% |
|---|---|---|---|---|---|
| 5.9% | $107 | $107 | $107 | $107 | $107 |
| 6.9% | $106 | $106 | $106 | $106 | $106 |
| 7.9% | $105 | $105 | $105 | $105 | $105 |
| 8.9% | $104 | $104 | $104 | $104 | $104 |
| 9.9% | $102 | $102 | $102 | $102 | $102 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |